Estrella Immunopharma, Inc. ESLA
Set alert
As of Nov 3, 11:02 AM ET
- YTD
- -74.29%
- 1 year
- -86.85%
- Open
- 0.429
- Prev close
- 0.4263
- Mkt cap
- 17.47M
- Vol
- 111.55K
- Avg vol
- 1.79M
- EPS
- -0.25
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.3946
- High
- 0.475
- Forward P/E
- 0.00
- Beta
- 0.24
- Short ratio
- 0.07
- Inst. own
- 0.55%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.97534
- 200-d avg
- 1.10
- 1y target
- 0.00
5m chart
Built from the cached five-day intraday bars.
Signals (134)
| Name | Time | Ago |
|---|---|---|
| MACD: Sell Signal | Nov 2, 2:35 PM | 20 hours ago |
| SMA: Bearish | Nov 2, 1:55 PM | 21 hours ago |
| SMA: Bearish | Nov 2, 1:45 PM | 21 hours ago |
| SMA: Bullish | Nov 2, 1:30 PM | 21 hours ago |
| SMA: Bullish | Nov 2, 1:30 PM | 21 hours ago |
| RSI: Oversold | Nov 2, 12:45 PM | 22 hours ago |
| SMA: Bearish | Nov 2, 12:20 PM | 22 hours ago |
| SMA: Bearish | Nov 2, 12:20 PM | 22 hours ago |
| SMA: Bullish | Nov 2, 12:15 PM | 22 hours ago |
| SMA: Bullish | Nov 2, 12:10 PM | 22 hours ago |
| SMA: Bearish | Nov 2, 11:40 AM | 23 hours ago |
| SMA: Bullish | Nov 2, 11:35 AM | 23 hours ago |
| SMA: Bearish | Nov 2, 10:50 AM | 1 day ago |
| MACD: Buy Signal | Nov 2, 10:45 AM | 1 day ago |
| SMA: Bullish | Nov 2, 10:40 AM | 1 day ago |
| RSI: Oversold | Nov 2, 9:30 AM | 1 day ago |
| MACD: Sell Signal | Oct 30, 3:55 PM | 3 days ago |
| SMA: Bearish | Oct 30, 3:50 PM | 3 days ago |
| SMA: Bearish | Oct 30, 3:50 PM | 3 days ago |
| SMA: Bullish | Oct 30, 3:45 PM | 3 days ago |
Newest 20 of 134.
Key statistics
- Market cap
- 40.88M
- Enterprise value
- 28.05M
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 9.58
- EPS (TTM)
- -0.24
- Beta
- 0.24
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -12.95M
- Total cash
- 4.17M
- Total debt
- 4.00K
- Return on equity
- 0.00%
- Shares outstanding
- 36.18M
- Short % of float
- 0.06%
- 50-day average
- 0.97534
- 200-day average
- 1.10
Analyst view
Consensus: none
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
About Estrella Immunopharma, Inc.
Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103, which is in clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It has a collaborative agreement with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. was founded in 2006 and is headquartered in EmeryVille, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- estrellabio.com
News
- Estrella Immunopharma Appoints Cynthia Pussinen CEO, Chairperson, Effective Oct. 25, Succeeding Cheng Liu
- Estrella Immunopharma Appoints Cynthia Pussinen as Chief Executive Officer and Chairperson of the Board of Directors
- 12 Health Care Stocks Moving In Friday's Intraday Session
- 12 Health Care Stocks Moving In Thursday's After-Market Session
- 12 Health Care Stocks Moving In Thursday's Intraday Session
- Estrella Immunopharma (ESLA) Stock Soars 18%: What’s Driving the Surge
- 12 Health Care Stocks Moving In Wednesday's Intraday Session
- 12 Health Care Stocks Moving In Monday's Intraday Session
- 12 Health Care Stocks Moving In Monday's Pre-Market Session
- Estrella Immunopharma Treats First Patient with Two EB103 Infusions in STARLIGHT-1 Dose-Expansion Phase
Your note
Sign in to keep a note on ESLA — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Geode Capital Management, LLC | 0.21% | 76,556 | 86.51K | Sep 29, 2024 |
| ATW Spac Management LLC | 0.11% | 40,000 | 45.20K | Sep 29, 2024 |
| Blackrock Inc. | 0.07% | 24,963 | 28.21K | Sep 29, 2024 |
| Vanguard Group Inc | 0.06% | 21,684 | 24.50K | Sep 29, 2024 |
| Citadel Advisors Llc | 0.04% | 14,531 | 16.42K | Sep 29, 2024 |
| Maso Capital Partners Ltd. | 0.03% | 10,000 | 11.30K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.16% | 56,779 | 64.16K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.06% | 22,435 | 25.35K | Oct 30, 2024 |
| Vanguard Total Stock Market Index Fund | 0.05% | 17,968 | 20.30K | Sep 29, 2024 |
| Fidelity Total Market Index Fund | 0.05% | 16,862 | 19.05K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.04% | 13,413 | 15.16K | Oct 30, 2024 |
| EQ Advisors Trust-1290 VT Micro Cap Port | 0.01% | 2,373 | 2.68K | Sep 29, 2024 |